14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:DRNA
Delisted

Dicerna Pharmaceuticals Stock Price (Quote)

$38.22
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 27th May 2022 DRNA stock ended at $38.22. During the day the stock fluctuated 0% from a day low at $38.22 to a day high of $38.22.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Dicerna Pharmaceuticals prices

Date Open High Low Close Volume
Jan 10, 2020 $22.19 $22.48 $21.66 $21.82 567 355
Jan 09, 2020 $22.93 $22.97 $21.95 $22.21 633 100
Jan 08, 2020 $21.42 $22.94 $21.30 $22.58 1 142 820
Jan 07, 2020 $21.40 $21.63 $21.06 $21.46 437 229
Jan 06, 2020 $21.17 $21.65 $20.59 $21.47 441 961
Jan 03, 2020 $21.75 $22.14 $20.73 $21.26 759 562
Jan 02, 2020 $22.27 $22.27 $21.65 $22.06 768 000
Dec 31, 2019 $21.76 $22.60 $21.65 $22.03 515 387
Dec 30, 2019 $22.17 $22.28 $21.42 $21.86 371 117
Dec 27, 2019 $22.56 $22.56 $21.61 $22.26 727 735
Dec 26, 2019 $23.11 $23.17 $22.41 $22.53 482 603
Dec 24, 2019 $23.15 $23.32 $22.72 $23.12 527 413
Dec 23, 2019 $23.26 $23.50 $22.59 $22.96 889 793
Dec 20, 2019 $26.07 $26.11 $23.07 $23.28 1 649 191
Dec 19, 2019 $26.15 $26.66 $25.86 $26.07 494 202
Dec 18, 2019 $27.12 $27.26 $25.35 $26.01 919 991
Dec 17, 2019 $26.96 $27.40 $25.70 $26.35 475 304
Dec 16, 2019 $27.10 $27.29 $26.56 $26.92 693 956
Dec 13, 2019 $26.75 $27.68 $26.16 $26.79 703 544
Dec 12, 2019 $26.14 $26.81 $25.93 $26.73 522 358
Dec 11, 2019 $26.08 $26.64 $25.69 $26.13 491 290
Dec 10, 2019 $25.40 $26.19 $24.96 $26.01 564 140
Dec 09, 2019 $26.43 $26.83 $24.22 $25.46 696 284
Dec 06, 2019 $26.71 $27.04 $26.01 $26.63 482 929
Dec 05, 2019 $26.94 $27.19 $25.96 $26.51 757 372
Click to get the best stock tips daily for free!

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherit... DRNA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT